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Dr. Janet Scott BSc(Hons) BMBCh PhD MRCP 
Clinical Lecturer in Pharmacology and Infectious Disease  
Clinical Lead, Convolescent Plasma for Early EVD & Survivor Studies 
Institute of Translational Medicine, Sherrington Building, 
University of Liverpool,  
Liverpool 
 
T  +447899892430 
S  Janet.T.Scott 
T @JTSGlobal Health @WQP1Adventure  
E  jscott@liverpool.ac.uk  
 
 
          21st October 2015 
 
Dear Dr. Drotman,  
 
Re: Characterising Post Ebola Syndrome: initial observations and future research agenda 
 
 
Thank you for sending the kind, helpful and detailed comments of the referees for this manuscript. I 
would appreciate when appropriate, if you could forward our thanks for their time please. The 
manuscript describes Post Ebola Syndrome (PES) in a complete unselected cohort of survivors of 
Ebola Virus Disease (Zaire) discharged from a single Ebola Treatment Unit. Thus it is to ascertain the 
proportion of survivors suffering from each symptom facilitating health care planning and future 
research. 
 
Please find attached a revised manuscript having responded to reviewers comment. The details are 
given below: 
 
I hope it is now acceptable for publication. 
. 
 
Yours sincerely, 
 
 
 
Dr. Janet Scott 
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Changes made: 
 
Note from the letter  
 
Claims of primacy have been removed. 
 
Figures to be uploaded in 300DPI. I note the instructions to authors requests 600 dpi – 
so this is what has been uploaded. 300dpi is possible, please do get back to me if this is 
preferred. 
 
Specific Reviewers comments: 
Regarding the short period of follow up the following has been added to the discussion:  
“Some complications occur weeks or months after the acute onset, so some symptoms 
may be underestimated in this cohort
2, 5.” 
 
Regarding the request to revise the time to follow up based on the second negative 
blood test: records of the time of the negative blood tests are not available in all cases, 
however patients tended to wait a weeks until their physical health and social situation 
were suitable for them to be discharged. The abstract has therefore been revised to 
‘within 3 weeks of negative PCR’ and this point made in more detail in the body of the 
text. 
 
Regarding a control group: Past medical histories were collected from these patients but 
were not extracted for analysis. In general whilst there is some musculoskeletal pain 
and issues with visual acuity patients were able to distinguish between what occurred 
post Ebola and what was prior. Pre-existing conditions have not been included in the 
‘problem lists’. We have now established a more comprehensive data base which 
should document these patients, over the months that have now past, and indeed the 
other 250 patients who have now also registered with the clinic. So this is an issue that 
should be better addressed in follow up data. 
 
Regarding preadmission CT values:  These are not readily available although we are 
making efforts to collate them for future reference. The laboratories worked on a rota 
system so they were processed and assayed on different days, in different laboratories 
and on different platforms. The laboratories included Godrich, (South African Team), 
Public Health England, Port Locco and Kerrytown and the Chinese CDC. Consequently 
a groupwise comparison would likely lack validity and anyway in our opinion add little 
information to this survey of initial sequelae. 
 
Regarding acknowledging that the convalescent whole blood was not powered to study 
its effect on PES: the following has been added to reflect that this is not a prospective 
study, so can no be claimed to be designed to detect a difference in treatment outcomes: 
 
 “23 of the survivors received CWB and 21 did not. There was no difference in age 
distribution of those transfused and those not transfused (p=0.8).  There was no 
difference in the frequencies of symptoms between patients who received CWB and 
those who did not (p=0.5). This primary report on post-Ebola symptoms is not designed 
to consider the question of efficacy or toxicity of CWB. 
 
The documentation of the patient who died has been extended. 
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All minor changes in the attachment have been acted on including: 
 
The section describing the ETU at MH34 has been shortened the section on data 
collection expanded.  
 
Point 10. The point is well taken that this is by no means meant as a secondary outcome 
of the compassionate use trial of convalescent whole blood, but rather as justification of 
our using both patients who did and did not receive it. This section has been modified 
to: 
“Symptoms do not appear to have been affected by use of CWB in the management of 
acute EVD. This finding should be interpreted with caution, as this report is not a 
prospective study and not designed to consider impact of CWB on PES..” 
 
Reviewer 1. (From the email) 
Line 96: Regarding time from second negative PCR to discharge. This information is 
not available in this data extraction, which was a simple documentation of problem lists 
by the first formal health check. Patients often come in informally in an ad hoc basis. 
Now the survivors clinic and data collection are more formalised,  future follow ups can 
be more precise. Discharge criteria has been moved to this point.  
 
Details of the age group and gender characteristics of musculoskeletal pain and ocular 
pain have been removed. There seems to be less children reporting headache than 
adults. Whilst the numbers would, in my opinion, be too small to draw any conclusions. 
we have left the numbers in the paper to they can be available for other studies in the 
future.  
 
This paper does not correlated the acute Ebola history post Ebola syndrome with illness 
severity and nor does it claim to – these patients along with about 250 others are being 
recruited to track their progress over the subsequent months and years where possible 
also collect data about their time as acute inpatients. Even for clinical trial patients 
however this has proved to be a much harder ask than it might seem and remains a 
work in progress. 
 
The reviewer thought that MH34 catered only to health care workers. This was not the 
case. MH34 although staffed by the military hospital mostly admits civilian from the 
Western Urban Area Freetown. I wonder if possibly the reviewer is thinking about the 
Kerrytown UK MoD military run unit that did only admit expatriate staff or health care 
workers.  
 
 
Thank you again for the comments, I hope the manuscript is now suitable for 
publication. 
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Summary 16 
 17 
Thousands have survived Ebola virus disease (EVD). Almost all survivors describe 18 
symptoms that persist or develop after discharge. We describe the symptoms in a complete 19 
unselected cohort of patients discharged from a single Ebola treatment unit (ETU). A cross-20 
sectional survey of the symptoms of all survivors from the ETU at 34
th
 Regimental Military 21 
Hospital, Freetown, Sierra Leone (MH34) was conducted after discharge at their initial 22 
follow-up appointment within three weeks of their second negative PCR. Between opening 23 
on 1
st
 December 2014, and 30
th
 March 2015 the MH34 ETU treated 84 people with PCR 24 
confirmed Ebola. 44 survived (21 males, 23 females, age 8 to 70 years old. Survivors 25 
complain of musculoskeletal pain (70%), headache (48%) and ocular problems (14%). This 26 
complete survivor cohort from a single ETU allows an analysis of the proportion of 27 
symptoms of Post Ebola Syndrome to be made. 28 
 29 
 30 
One Line summary:  31 
A cross sectional survey of Post Ebola Syndrome within three weeks of second negative PCR 32 
from a complete unselected cohort indicated Ebola survivors suffer from a range of 33 
conditions which are dominated by musculoskeletal pain (70%), headache (48%) and ocular 34 
problems (14%).  35 
 36 
Biography of First Author. 37 
 38 
Dr Janet Scott is a Clinical Lecturer in Pharmacology and Infectious Diseases at the Institute 39 
of Translational Medicine, University of Liverpool. 40 
  41 
Page 6 of 46
ScholarOne support: (434) 964-4100
Emerging Infectious Diseases
Peer Review
 3
 42 
Thousands of people have now survived Ebola Virus Disease (EVD). In the fight to 43 
control the current Ebola-Zaire outbreak, attention has focused on containing the spread of 44 
infection and improving survival of the sick. It is estimated that there are between 4051 and 45 
5115 survivors in Sierra Leone (8704 confirmed cases, 3589 confirmed deaths, 4051 46 
confirmed discharges 
1
).  47 
 48 
Survivors complain of a range of sequelae loosely described as 'Post Ebola Syndrome' (PES). 49 
Follow-up clinics were not always planned as part of the emergency response. However, 50 
survivors from the ETU at the 34
th
 Regimental Military Hospital, Wilberforce Barracks, 51 
Freetown, Sierra Leone (MH34) were all followed up in an outpatient clinic within two 52 
weeks of discharge. Although resources for the care of survivors, including basic equipment 53 
such as adequate stethoscopes was scarce at this time, each survivor was seen by a physician 54 
who made contemporaneous structured notes. This affords an opportunity to document PES 55 
in these first weeks. 56 
 57 
It is not clear what proportion of Ebola survivors are suffering sequelae. Little is known about 58 
‘Post Ebola Syndrome', or even if it is an entity distinct from an appropriate response to the 59 
traumatic events. Abdominal pains, loss of vision, loss of hearing, impotence, bleeding, 60 
psychological problems, and general weakness were listed qualitatively as symptoms of PES, 61 
following the Ebola-Sudan outbreak (Uganda 2000)
2
. Arthralgia and ocular diseases, were 62 
noted in 19 survivors (selected according to availability) who were followed up after the 63 
Ebola-Zaire outbreak in Kikwit  (1995) 
3, 4
 and in the same outbreak, arthralgia, myalgia, 64 
abdominal pain, extreme fatigue and anorexia were more common in Ebola survivors than in 65 
household contacts 
5
. From the current outbreak, survivors reported arthralgia and “anorexia” 66 
(which in this context includes loss of appetite without weight loss) in a telephone 67 
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administered questionnaire in Guinea when asked some months after discharge
6
. None of 68 
these studies were an unselected cohort of survivors so interpretation of proportions was 69 
difficult. Other reports refer to anecdotes of pain, weakness, difficulty hearing and ‘mental 70 
disturbances
7, 8
. These observations give some idea of what complaints might be expected. 71 
Describing the proportions needing care for the most common problems is important for 72 
planning the health care of the thousands of survivors. We report the symptoms described by 73 
all survivors from one Ebola treatment unit (ETU) in the initial weeks after discharge. 74 
 75 
  76 
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Methods. 77 
The MH34 ETU is a facility that could care for up to 30 confirmed cases of EVD, plus 20 78 
suspect cases. It opened on 1
st
 December 2014 with 115 staff including 3 doctors. It catered 79 
for patients falling ill in Western Freetown and surrounds. The ETU admitted 355 patients, 84 80 
positive patients and discharged 44 survivors between December and March 2015. The ETU 81 
at MH34 consists of a suspect and confirmed areas and a doffing area. The confirmed zone is 82 
a permanent building including several one to four bedded rooms with electric lighting and 83 
ceiling fans. Three hot meals per day are provided, generally rice with protein such as fish or 84 
chicken; each with two bags of water. The staff of this small ETU are all permanent Sierra 85 
Leonean health care workers. 86 
 87 
Patients were treated for EVD, with supportive care 
9
. At the MH34 empirical antibiotics and 88 
artesunate, paracetamol, and 500ml intravenous Ringer’s Lactate were administered on 89 
arrival. On-going treatment included: further boluses of intravenous fluid, antiemetic’s and 90 
proton pump inhibitors; that were administered according to clinical need. Some patients 91 
participated in a compassionate use open non-randomised study of a single unit of 92 
convalescent whole blood (CWB), results of which are pending.  93 
 94 
Discharge criteria were: two consecutive negative EBOV PCR tests taken on separate days; 95 
medically fit in the opinion of their physician; and when adequate social provision had been 96 
made, including when their house and household members being released from quarantine.  97 
Records of the dates of individual negative PCRs are unfortunately not available, however 98 
patients tended to stay and convalesce in the ETU for about a week after their negative 99 
results. During the convalescent period many patients ate more than one serving of each 100 
meal, three times a day. Although they were not routinely weighed most patients visibly 101 
gained weight.  102 
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 103 
All survivors were issued with a survivor’s certificate on leaving the ETU and invited to a 104 
follow-up appointment within two weeks of discharge. Some were seen prior to this 105 
appointment due to clinical need.  106 
 107 
Contact with survivors was maintained by mobile phone. Confirmation of identification has 108 
not proved problematic, as the patients and health care workers had come to know each other 109 
well. Appointments are made by mobile phone and unscheduled visits by patients to the 110 
hospital.  All survivors attended their follow-up. Patients were examined by one of three 111 
experienced physicians.  112 
 113 
A follow-up appointment was established as a standard of care in this ETU from the outset, at 114 
the height of the epidemic. Handwritten clinical notes were taken documenting presenting 115 
complaints, symptoms and signs. These notes were subsequently used to develop appropriate 116 
pre-printed clinical documentation. Age, sex, presenting complaints, and history of 117 
transfusion with CWB were noted for each patient.  Pre-existing conditions were rare in this 118 
cohort of patients, and not included in this data extraction.  At that time facilities and 119 
equipment for survivors was very limited. For example all stethoscopes had been incinerated; 120 
blood pressure cuffs, ophthalmoscopes, and specialist opinions were not available.  121 
 122 
Data Analysis. 123 
Confidence intervals and hypothesis testing of binomial outcomes (binomial frequency test) 124 
were analysed using Stata v9 (StataCorp LP, Texas USA) 
10
. Graphics were produced using 125 
Stata v9 and R v3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). 126 
  127 
  128 
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Results 129 
Between opening on 1
st
 December 2014, and 30
th
 March 2015 the MH34 ETU had treated 84 130 
people with PCR confirmed EVD. 44 survived (21 male, 23 female, age range 8 to 70 years 131 
old median age 35 years (IQR 20-37yr), age not documented in 1 case)) (Figure 1). 23 of the 132 
survivors received CWB and 21 did not. There was no difference in age distribution of those 133 
transfused and those not transfused (p=0.8).  There was no difference in the frequencies of 134 
symptoms between patients who received CWB and those who did not (p=0.5). This primary 135 
report on post-Ebola symptoms is not designed to consider the question of efficacy or toxicity 136 
of CWB. 137 
 138 
At the time of this data extraction each patient had attended a maximum of two appointments. 139 
All survivors presented with at least one post Ebola complaint, a median of 2 complaints and 140 
a maximum of 5. 117 separate presenting complaints were reported. 70% of patients suffered 141 
from musculoskeletal pain (31/44 CI 55-83%), 48% of patients (21/44, CI 32-63%) suffered 142 
from headaches and 14% of patients (6/44, CI 5-27%) suffered from ocular problems.  143 
 144 
One patient died following gradually deteriorating respiratory symptoms and a left sided 145 
pleural effusion. He was a 25 year old man, diagnosed with Ebola on 26
th
 January, and 146 
treated with supportive care and 1 unit of CWB. He received his first negative PCR result on 147 
8
th
 February and his confirmatory negative test on 11
th
 February, and was discharged home. 148 
At his 14 day follow-up he was noted to have weight loss, cough and dyspnoea on exertion. 149 
He was admitted on his second outpatient appointment to the general medical ward on 3
rd
 150 
March 2015 with a left sided pleural effusion. A pleural tap was attempted, but yielded only a 151 
small quantity of blood stained fluid that was insufficient for analysis. He died after a short 152 
inpatient stay on 8
th
 March 2015, a month after his recovery from acute EVD. Adhering to 153 
safe-burial policy, a post-mortem examination was not performed. His diagnosis remains 154 
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unclear but a post-viral effusion is possible with tuberculosis pleural effusion being a 155 
differential diagnosis.  156 
 157 
Musculoskeletal Pain. 158 
70% of patients (31/44, CI 55-83%) suffered from musculoskeletal pain. In our experience 159 
and in the local context the distinction between myalgia and arthralgia can be a doctor 160 
dependent label. In these circumstances we chose to merge these complaints. However for the 161 
purposes of comparisons with other studies, 12/44 (27% CI: 15-42%) had problems labelled 162 
as ‘arthralgia’ , 15/44 (27% CI: 20-50%) had ‘myalgia’ and 4/44 (9%  CI 3-22%) had both.  163 
Individual problems are listed in Table 1. There were no statistically significant differences 164 
between the proportion of males and females; nor children (<18 years) and adults suffering 165 
from musculoskeletal pain. 166 
 167 
Musculoskeletal pain is variously described by patients as problems with walking or moving, 168 
or pain specific to one area, such as knees, thighs or back, or a generalised musculoskeletal 169 
pain (21-52%.)  The picture is more often one of a general pain rather than a specific joint or 170 
area. This is reflected in the recorded symptoms, the most common of which are unspecified 171 
joint pain (36%, 14/39 CI 21-52% recorded) and generalised body pain (21%: 8/39 CI 9-172 
36%)  (Table 1).  173 
 174 
On examination there is no indication of inflamed joints or joint effusions, such as might be 175 
expected in a reactive picture and a full range of movement is retained. A description of 176 
functional disability suggests that the range is from mild to moderate. For example, one male 177 
patient in his twenties, continues to play football, but now takes paracetamol (acetaminophen) 178 
to facilitate this, whereas another female patient in her forties requires assistance to step into 179 
a bath and is no longer able to continue normal household work. She was able to walk 180 
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unaided into clinic, but needed assistance to step up into the clinic room and to sit and stand. 181 
Most musculoskeletal symptoms are relieved by simple analgesia. 182 
 183 
Headache 184 
48% of patients (21/44, CI 32-63%) suffered from headaches.   Two (of Twenty-one) (10%, 185 
CI 1-30%) of these were children, both female and aged 8 and 11 years.  There was no 186 
statistically significant difference between the proportion of males and females suffering 187 
from headaches (Chi
2
, p=1). Headache is generally described as affecting the full head, with 188 
no diurnal pattern and being constant. Ocular symptoms may coincide, but there are no visual 189 
phenomena reported such as might be found in migraine. These symptoms could represent 190 
on-going tension headaches, or may be a result of underlying undiagnosed changes in vision.  191 
 192 
Ocular Symptoms 193 
14% of patients (6/44, CI 5-27%) suffered from ocular problems. Symptoms included eye 194 
pain, clear eye discharge, red eyes and blurred vision (Table 2). These symptoms appeared 195 
within 2 weeks of discharge and were not present at discharge from the ETU or before. At 196 
this time the facility for ophthalmology review was not available. Eye discharge was treated 197 
with topical chloramphenicol. Ophthalmology services for survivors are currently under 198 
development. 199 
 200 
Combinations of Musculoskeletal Pain, Headache and Ocular problems. 201 
There is a substantial overlap between the presentation of musculoskeletal pain and headache. 202 
18 patients complained of both. This is 58% (18/31, CI 40-75%) of patients with 203 
musculoskeletal pain and 86% (18/21, CI 64-97%) of patients with headache.  Two patients 204 
had both ocular problems and musculoskeletal pain. This was 6% (2/31, CI 1-21%) of 205 
patients with musculoskeletal pain and 33% (2/6, CI 4-78%) of patients with ocular 206 
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problems.  Two patients had both headache and ocular problems (2/21, 6%, CI 1-30% of 207 
patients with headache). One patient had all three complaints (1/31, 3% 1-17% of patients 208 
with musculoskeletal pain, 1/21, 5%, CI 0-24% of patients with headache and 15% 1/6, CI 0-209 
64% of patients with ocular problems). These relationships are graphically described in a 210 
scaled Venn diagram (Figure 2). 211 
 212 
Other Symptoms 213 
60% of patients (26/44, CI 43-74%) suffered from other symptoms. 11% (5/44, CI 4-25) 214 
complained of cough, 9% (4/44, CI 3-22%) complained of abdominal pain, 9% of chest pain, 215 
and 9% of itching. 7% (3/44 CI 1-19%) complained of insomnia, 7% fever and 7%  loss of 216 
appetite, 5% (2/44 1-15%) complained of laboured speech, 5% epigastric pain and 5% rash, 217 
and the remaining symptoms were reported by one person each (2% CI 0-12%). These other 218 
symptoms were: weight loss, hiccups, increased appetite, chest pain, sneezing, diarrhoea, 219 
vomiting, left sided weakness with facial nerve palsy, breathlessness, rash, dry flaky skin, 220 
earache, fever blister/cold sore, left scrotal swelling, nasal congestion and tremors. 221 
 222 
  223 
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Discussion. 224 
This survey documents symptoms of Ebola survivors in the initial three weeks post negative 225 
EBOV PCR and two weeks after discharge from the treatment centre. The dominant clinical 226 
features exhibited by this survivor cohort were musculoskeletal pain, headache, and ocular 227 
problems. Symptoms did not differ with gender or age in this cohort. Symptoms do not 228 
appear to have been affected by use of CWB in the management of acute EVD. This finding 229 
should be interpreted with caution, as this report is not a prospective study and not designed 230 
to consider impact of CWB on PES. Whether this collection of signs and symptoms 231 
experienced after acute EVD constitute a separate ‘syndrome’ or not may be semantic 232 
argument. The experience of patients in the weeks after Ebola, although varied, has common 233 
features so we propose that the term Post Ebola Syndrome (PES) is useful to describe these 234 
phenomena. 235 
 236 
Our findings are consistent with some aspects of previous reports 
2, 5
 but vary from others. 237 
For example, the prevalence of extreme fatigue and anorexia reported in Kikwit and Guinea 
5, 
238 
6
 has not been dominant in this cohort. This may be due to the period of inpatient 239 
convalescence that the survivors had at MH34 with substantial nutritional support.  240 
 241 
We hypothesise that the pathogenesis of pain, particularly the muscle pain is a sequelae of 242 
widespread myositis or rhabdomyolysis during acute EVD. This would be consistent with 243 
laboratory data reporting raised transaminases and disseminated intravascular coagulation 244 
from a previous outbreak of Sudan EVD 
11
. Future research would benefit from a comparison 245 
of a survivors cohort with a matched group who had not had Ebola and, if this pain is more 246 
common in Ebola survivors (as was found in Kikwit 
5
), further elucidation of its aetiology 247 
would be useful in determining treatment strategies. 248 
 249 
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PES includes musculoskeletal pain, headache and ocular problems but is not restricted to 250 
these areas. Some complications occur weeks or months after the acute onset, so some 251 
symptoms may be underestimated in this cohort
2, 5
.  Since this data was extracted clinical 252 
facilities and documentation has improved so future information is likely to be more detailed 253 
in terms of specific diagnosis, and scope. This is particularly true in the areas of psycho-254 
social health and ophthalmology. Previous outbreaks have reported psychosocial problems 
2
 255 
although it is not included in all reports 
5
. Psycho-social problems are also evident in our 256 
patient group, although not captured in the documentation to date. Improved collaboration 257 
with the hospital’s mental health team should improve both the care and documentation in the 258 
future. Anecdotal evidence from the survivors’ clinic suggests that more subtle neurological 259 
problems such as specific nerve palsies may feature more heavily in a follow-up study.   260 
 261 
We would expect that the criteria and definition of PES will continue to develop and that the 262 
patients continue to present with fresh challenges. During the height of the epidemic, when 263 
these consultations took place, resources, and equipment for assessing survivors was very 264 
limited. This survey documents symptoms only in the first two weeks of discharge. 265 
Subsequent follow-up may be more detailed and benefit from increased resources, and 266 
symptoms continue to develop with time. Indeed the virus can cross the blood brain barrier 267 
during the acute illness 
12
 , and persist in some compartments for some months
13
 .  PES may 268 
continue to present new challenges.  Areas for development include: comparison of 269 
symptoms to community controls, psycho-social problems, the aetiology of ocular problems 270 
and musculoskeletal pain, and longitudinal description of the clinical picture.  271 
 272 
Musculoskeletal pain is a common complaint in the general population in Sierra Leone so a 273 
community controlled comparison will be important. In survivors of the Kikwit Ebola Zaire 274 
outbreak in 1995, Rowe et al. reported that their key features: Arthralgia, myalgia, abdominal 275 
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pain, fatigue and anorexia were more common in convalescents than household contacts, 276 
whereas fever, headache, diarrhoea, dyspnea, hiccups, haemorrhage were the same in 277 
survivors and the control group
5
. A topic for future research is the longitudinal course of 278 
recovery. Wendo et al 
2
 report that one year after the Ebola Zaire outbreak in Uganda, 25% of 279 
patients were still reporting to clinic. We can expect therefore some patients to have long 280 
term clinical needs. The epidemic is waning but the burden of disease it caused will remain 281 
for some time to come. 282 
 283 
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 334 
 335 
 336 
 337 
Note to editors: The image of the histogram has been uploaded separately as a 600dpi tif file. 338 
We would envisage this being presented in conjunction with this small table as a single 339 
figure. I have left this separate according to the instructions to authors to maximise 340 
editability. 341 
 342 
 343 
  344 
Figure 1.  Age distribution of patients presenting to the 34
th
 Military Hospital Ebola 
Survivor’s Clinic.  
 Male Female Total 
N 21 22 44 
Median 30 25 25 
IQR 22-37 20-34 20-37 
Range 10-52 8-70 8-70 
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Table 1: The frequencies of musculoskeletal symptoms. 
Some individuals complained of more than one area of pain. 
There was no statistically significant difference between the 
proportion of males and females suffering from 
musculoskeletal pain. (Chi
2
, p=0.7). 
 
 
  
Sex 
Area of Pain Male Female Total 
Joint  Unspecified 5 9 14 
Knee Unspecified 2 0 2 
Right Knee Joint 0 1 1 
Shoulder Joint 1 1 2 
Generalised Body 4 4 8 
Upper Back Pain 1 3 4 
Musculo-skeletal  
Unspecified 2 0 2 
Left Thigh 1 1 2 
Lower Limb 0 1 1 
Right Thigh 1 0 1 
Gluteal Muscle 1 0 1 
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Table 2:  Ocular Symptoms: described by patients. Two patients were children and four were 346 
adults.  347 
 348 
Age Sex Symptom 
8 F eye pain 
14 F clear eye discharge 
20 F clear eye discharge 
28 F red eyes and 
blurred vision on 
the left 
29 F red eyes 
46 M blurred vision 
 349 
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Table 3: Number of patients presenting with of other presenting complaints 351 
Presenting 
Complaint 
N % Confidence 
Intervals 
(%) 
Cough 5 11 4-25 
Abdominal pain 4 9 3-22 
Chest pain 4 9 3-22 
Itching 4 9 3-22 
Insomnia 3 7 1-19 
Fever 3 7 1-19 
Loss of appetite 3 7 1-19 
Laboured speech 2 5 1-15 
Epigastric pain 2 5 1-15 
Rash 2 5 1-5 
17 other 
symptoms* 
1 2 0-12 
 352 
*Weight Loss, Hiccups, increased appetite, chest pain, sneezing, diarrhoea, vomiting, left 353 
sided weakness with facial nerve palsy, breathlessness, rash, dry flaky skin, earache, fever 354 
blister/cold sore, left scrotal swelling, nasal congestion, tremors 355 
 356 
 357 
  358 
Page 23 of 46
ScholarOne support: (434) 964-4100
Emerging Infectious Diseases
Peer Review
 20 
Figure 2. 359 
A scale Venn diagram illustrating the overlap between the three main symptom groups.  360 
Seven patients did not have any other the three main symptom groups. 361 
 362 
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 364 
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 370 
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Summary 16 
 17 
Thousands have survived Ebola virus disease (EVD). Almost all survivors describe 18 
symptoms that persist or develop after discharge. We describe the symptoms in a complete 19 
unselected cohort of patients discharged from a single Ebola treatment unit (ETU). A cross-20 
sectional survey of the symptoms of all survivors from the ETU at 34
th
 Regimental Military 21 
Hospital, Freetown, Sierra Leone (MH34) was conducted after discharge at their initial 22 
follow-up appointment within three weeks of their second negative PCR. Between opening 23 
on 1
st
 December 2014, and 30
th
 March 2015 the MH34 ETU treated 84 people with PCR 24 
confirmed Ebola. 44 survived (21 males, 23 females, age 8 to 70 years old. Survivors 25 
complain of musculoskeletal pain (70%), headache (48%) and ocular problems (14%). This 26 
complete survivor cohort from a single ETU allows an analysis of the proportion of 27 
symptoms of Post Ebola Syndrome to be made. 28 
 29 
 30 
One Line summary:  31 
A cross sectional survey of Post Ebola Syndrome within three weeks of second negative PCR 32 
from a complete unselected cohort indicated Ebola survivors suffer from a range of 33 
conditions which are dominated by musculoskeletal pain (70%), headache (48%) and ocular 34 
problems (14%).  35 
 36 
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 42 
Thousands of people have now survived Ebola Virus Disease (EVD). In the fight to 43 
control the current Ebola-Zaire outbreak, attention has focused on containing the spread of 44 
infection and improving survival of the sick. It is estimated that there are between 4051 and 45 
5115 survivors in Sierra Leone (8704 confirmed cases, 3589 confirmed deaths, 4051 46 
confirmed discharges 
1
).  47 
 48 
Survivors complain of a range of sequelae loosely described as 'Post Ebola Syndrome' (PES). 49 
Follow-up clinics were not always planned as part of the emergency response. However, 50 
survivors from the ETU at the 34
th
 Regimental Military Hospital, Wilberforce Barracks, 51 
Freetown, Sierra Leone (MH34) w re all followed up in an outpatient clinic within two 52 
weeks of discharge. Although resources for the care of survivors, including basic equipment 53 
such as adequate stethoscopes was scarce at this time, each survivor was seen by a physician 54 
who made contemporaneous structured notes. This affords an opportunity to document PES 55 
in these first weeks. 56 
 57 
It is not clear what proportion of Ebola survivors are suffering sequelae. Little is known about 58 
‘Post Ebola Syndrome', or even if it is an entity distinct from an appropriate response to the 59 
traumatic events. Abdominal pains, loss of vision, loss of hearing, impotence, bleeding, 60 
psychological problems, and general weakness were listed qualitatively as symptoms of PES, 61 
following the Ebola-Sudan outbreak (Uganda 2000)
2
. Arthralgia and ocular diseases, were 62 
noted in 19 survivors (selected according to availability) who were followed up after the 63 
Ebola-Zaire outbreak in Kikwit  (1995) 
3, 4
 and in the same outbreak, arthralgia, myalgia, 64 
abdominal pain, extreme fatigue and anorexia were more common in Ebola survivors than in 65 
household contacts 
5. From the current outbreak, survivors reported arthralgia and “anorexia” 66 
(which in this context includes loss of appetite without weight loss) in a telephone 67 
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administered questionnaire in Guinea when asked some months after discharge
6
. None of 68 
these studies were an unselected cohort of survivors so interpretation of proportions was 69 
difficult. Other reports refer to anecdotes of pain, weakness, difficulty hearing and ‘mental 70 
disturbances
7, 8
. These observations give some idea of what complaints might be expected. 71 
Describing the proportions needing care for the most common problems is important for 72 
planning the health care of the thousands of survivors. We report the symptoms described by 73 
all survivors from one Ebola treatment unit (ETU) in the initial weeks after discharge. 74 
 75 
  76 
Page 28 of 46
ScholarOne support: (434) 964-4100
Emerging Infectious Diseases
Peer Review
 5 
Methods. 77 
The MH34 ETU is a facility that could care for up to 30 confirmed cases of EVD, plus 20 78 
suspect cases. It opened on 1
st
 December 2014 with 115 staff including 3 doctors. It catered 79 
for patients falling ill in Western Freetown and surrounds. The ETU admitted 355 patients, 84 80 
positive patients and discharged 44 survivors between December and March 2015. The ETU 81 
at MH34 consists of a suspect and confirmed areas and a doffing area. The confirmed zone is 82 
a permanent building including several one to four bedded rooms with electric lighting and 83 
ceiling fans. Three hot meals per day are provided, generally rice with protein such as fish or 84 
chicken; each with two bags of water. The staff of this small ETU are all permanent Sierra 85 
Leonean health care workers. 86 
 87 
Patients were treated for EVD, with supportive care 
9
. At the MH34 empirical antibiotics and 88 
artesunate, paracetamol, and 500ml intravenous Ringer’s Lactate were administered on 89 
arrival. On-going treatment included: further boluses of intravenous fluid, antiemetic’s and 90 
proton pump inhibitors; that were administered according to clinical need. Some patients 91 
participated in a compassionate use open non-randomised study of a single unit of 92 
convalescent whole blood (CWB), results of which are pending.  93 
 94 
Discharge criteria were: two consecutive negative EBOV PCR tests taken on separate days; 95 
medically fit in the opinion of their physician; and when adequate social provision had been 96 
made, including when their house and household members being released from quarantine.  97 
Records of the dates of individual negative PCRs are unfortunately not available, however 98 
patients tended to stay and convalesce in the ETU for about a week after their negative 99 
results. During the convalescent period many patients ate more than one serving of each 100 
meal, three times a day. Although they were not routinely weighed most patients visibly 101 
gained weight.  102 
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 103 
All survivors were issued with a survivor’s certificate on leaving the ETU and invited to a 104 
follow-up appointment within two weeks of discharge. Some were seen prior to this 105 
appointment due to clinical need.  106 
 107 
Contact with survivors was maintained by mobile phone. Confirmation of identification has 108 
not proved problematic, as the patients and health care workers had come to know each other 109 
well. Appointments are made by mobile phone and unscheduled visits by patients to the 110 
hospital.  All survivors attended their follow-up. Patients were examined by one of three 111 
experienced physicians.  112 
 113 
A follow-up appointment was established as a standard of care in this ETU from the outset, at 114 
the height of the epidemic. Handwritten clinical notes were taken documenting presenting 115 
complaints, symptoms and signs. These notes were subsequently used to develop appropriate 116 
pre-printed clinical documentation. Age, sex, presenting complaints, and history of 117 
transfusion with CWB were noted for each patient.  Pre-existing conditions were rare in this 118 
cohort of patients, and not included in this data extraction.  At that time facilities and 119 
equipment for survivors was very limited. For example all stethoscopes had been incinerated; 120 
blood pressure cuffs, ophthalmoscopes, and specialist opinions were not available.  121 
 122 
Data Analysis. 123 
Confidence intervals and hypothesis testing of binomial outcomes (binomial frequency test) 124 
were analysed using Stata v9 (StataCorp LP, Texas USA) 
10
. Graphics were produced using 125 
Stata v9 and R v3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). 126 
  127 
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Results 129 
Between opening on 1
st
 December 2014, and 30
th
 March 2015 the MH34 ETU had treated 84 130 
people with PCR confirmed EVD. 44 survived (21 male, 23 female, age range 8 to 70 years 131 
old median age 35 years (IQR 20-37yr), age not documented in 1 case)) (Figure 1). 23 of the 132 
survivors received CWB and 21 did not. There was no difference in age distribution of those 133 
transfused and those not transfused (p=0.8).  There was no difference in the frequencies of 134 
symptoms between patients who received CWB and those who did not (p=0.5). This primary 135 
report on post-Ebola symptoms is not designed to consider the question of efficacy or toxicity 136 
of CWB. 137 
 138 
At the time of this data extraction each patient had attended a maximum of two appointments. 139 
All survivors presented with at least one post Ebola complaint, a median of 2 complaints and 140 
a maximum of 5. 117 separate presenting complaints were reported. 70% of patients suffered 141 
from musculoskeletal pain (31/44 CI 55-83%), 48% of patients (21/44, CI 32-63%) suffered 142 
from headaches and 14% of patients (6/44, CI 5-27%) suffered from ocular problems.  143 
 144 
One patient died following gradually deteriorating respiratory symptoms and a left sided 145 
pleural effusion. He was a 25 year old man, diagnosed with Ebola on 26
th
 January, and 146 
treated with supportive care and 1 unit of CWB. He received his first negative PCR result on 147 
8
th
 February and his confirmatory negative test on 11
th
 February, and was discharged home. 148 
At his 14 day follow-up he was noted to have weight loss, cough and dyspnoea on exertion. 149 
He was admitted on his second outpatient appointment to the general medical ward on 3
rd
 150 
March 2015 with a left sided pleural effusion. A pleural tap was attempted, but yielded only a 151 
small quantity of blood stained fluid that was insufficient for analysis. He died after a short 152 
inpatient stay on 8
th
 March 2015, a month after his recovery from acute EVD. Adhering to 153 
safe-burial policy, a post-mortem examination was not performed. His diagnosis remains 154 
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unclear but a post-viral effusion is possible with tuberculosis pleural effusion being a 155 
differential diagnosis.  156 
 157 
Musculoskeletal Pain. 158 
70% of patients (31/44, CI 55-83%) suffered from musculoskeletal pain. In our experience 159 
and in the local context the distinction between myalgia and arthralgia can be a doctor 160 
dependent label. In these circumstances we chose to merge these complaints. However for the 161 
purposes of comparisons with other studies, 12/44 (27% CI: 15-42%) had problems labelled 162 
as ‘arthralgia’ , 15/44 (27% CI: 20-50%) had ‘myalgia’ and 4/44 (9%  CI 3-22%) had both.  163 
Individual problems are listed in Table 1. There were no statistically significant differences 164 
between the proportion of males and females; nor children (<18 years) and adults suffering 165 
from musculoskeletal pain. 166 
 167 
Musculoskeletal pain is variously described by patients as problems with walking or moving, 168 
or pain specific to one area, such as knees, thighs or back, or a generalised musculoskeletal 169 
pain (21-52%.)  The picture is more often one of a general pain rather than a specific joint or 170 
area. This is reflected in the recorded symptoms, the most common of which are unspecified 171 
joint pain (36%, 14/39 CI 21-52% recorded) and generalised body pain (21%: 8/39 CI 9-172 
36%)  (Table 1).  173 
 174 
On examination there is no indication of inflamed joints or joint effusions, such as might be 175 
expected in a reactive picture and a full range of movement is retained. A description of 176 
functional disability suggests that the range is from mild to moderate. For example, one male 177 
patient in his twenties, continues to play football, but now takes paracetamol (acetaminophen) 178 
to facilitate this, whereas another female patient in her forties requires assistance to step into 179 
a bath and is no longer able to continue normal household work. She was able to walk 180 
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unaided into clinic, but needed assistance to step up into the clinic room and to sit and stand. 181 
Most musculoskeletal symptoms are relieved by simple analgesia. 182 
 183 
Headache 184 
48% of patients (21/44, CI 32-63%) suffered from headaches.   Two (of Twenty-one) (10%, 185 
CI 1-30%) of these were children, both female and aged 8 and 11 years.  There was no 186 
statistically significant difference between the proportion of males and females suffering 187 
from headaches (Chi
2
, p=1). Headache is generally described as affecting the full head, with 188 
no diurnal pattern and being constant. Ocular symptoms may coincide, but there are no visual 189 
phenomena reported such as might be found in migraine. These symptoms could represent 190 
on-going tension headaches, or may be a result of underlying undiagnosed changes in vision.  191 
 192 
Ocular Symptoms 193 
14% of patients (6/44, CI 5-27%) suffered from ocular problems. Symptoms included eye 194 
pain, clear eye discharge, red eyes and blurred vision (Table 2). These symptoms appeared 195 
within 2 weeks of discharge and were not present at discharge from the ETU or before. At 196 
this time the facility for ophthalmology review was not available. Eye discharge was treated 197 
with topical chloramphenicol. Ophthalmology services for survivors are currently under 198 
development. 199 
 200 
Combinations of Musculoskeletal Pain, Headache and Ocular problems. 201 
There is a substantial overlap between the presentation of musculoskeletal pain and headache. 202 
18 patients complained of both. This is 58% (18/31, CI 40-75%) of patients with 203 
musculoskeletal pain and 86% (18/21, CI 64-97%) of patients with headache.  Two patients 204 
had both ocular problems and musculoskeletal pain. This was 6% (2/31, CI 1-21%) of 205 
patients with musculoskeletal pain and 33% (2/6, CI 4-78%) of patients with ocular 206 
Page 33 of 46
ScholarOne support: (434) 964-4100
Emerging Infectious Diseases
Peer Review
 10 
problems.  Two patients had both headache and ocular problems (2/21, 6%, CI 1-30% of 207 
patients with headache). One patient had all three complaints (1/31, 3% 1-17% of patients 208 
with musculoskeletal pain, 1/21, 5%, CI 0-24% of patients with headache and 15% 1/6, CI 0-209 
64% of patients with ocular problems). These relationships are graphically described in a 210 
scaled Venn diagram (Figure 2). 211 
 212 
Other Symptoms 213 
60% of patients (26/44, CI 43-74%) suffered from other symptoms. 11% (5/44, CI 4-25) 214 
complained of cough, 9% (4/44, CI 3-22%) complained of abdominal pain, 9% of chest pain, 215 
and 9% of itching. 7% (3/44 CI 1-19%) complained of insomnia, 7% fever and 7%  loss of 216 
appetite, 5% (2/44 1-15%) complained of laboured speech, 5% epigastric pain and 5% rash, 217 
and the remaining symptoms were reported by one person each (2% CI 0-12%). These other 218 
symptoms were: weight loss, hiccups, increased appetite, chest pain, sneezing, diarrhoea, 219 
vomiting, left sided weakness with facial nerve palsy, breathlessness, rash, dry flaky skin, 220 
earache, fever blister/cold sore, left scrotal swelling, nasal congestion and tremors. 221 
 222 
  223 
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Discussion. 224 
This survey documents symptoms of Ebola survivors in the initial three weeks post negative 225 
EBOV PCR and two weeks after discharge from the treatment centre. The dominant clinical 226 
features exhibited by this survivor cohort were musculoskeletal pain, headache, and ocular 227 
problems. Symptoms did not differ with gender or age in this cohort. Symptoms do not 228 
appear to have been affected by use of CWB in the management of acute EVD. This finding 229 
should be interpreted with caution, as this report is not a prospective study and not designed 230 
to consider impact of CWB on PES. Whether this collection of signs and symptoms 231 
experienced after acute EVD constitute a separate ‘syndrome’ or not may be semantic 232 
argument. The experience of patients in the weeks after Ebola, although varied, has common 233 
features so we propose that the term Post Ebola Syndrome (PES) is useful to describe these 234 
phenomena. 235 
 236 
Our findings are consistent with some aspects of previous reports 
2, 5
 but vary from others. 237 
For example, the prevalence of extreme fatigue and anorexia reported in Kikwit and Guinea 
5, 
238 
6
 has not been dominant in this cohort. This may be due to the period of inpatient 239 
convalescence that the survivors had at MH34 with substantial nutritional support.  240 
 241 
We hypothesise that the pathogenesis of pain, particularly the muscle pain is a sequelae of 242 
widespread myositis or rhabdomyolysis during acute EVD. This would be consistent with 243 
laboratory data reporting raised transaminases and disseminated intravascular coagulation 244 
from a previous outbreak of Sudan EVD 
11
. Future research would benefit from a comparison 245 
of a survivors cohort with a matched group who had not had Ebola and, if this pain is more 246 
common in Ebola survivors (as was found in Kikwit 
5
), further elucidation of its aetiology 247 
would be useful in determining treatment strategies. 248 
 249 
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PES includes musculoskeletal pain, headache and ocular problems but is not restricted to 250 
these areas. Some complications occur weeks or months after the acute onset, so some 251 
symptoms may be underestimated in this cohort
2, 5
.  Since this data was extracted clinical 252 
facilities and documentation has improved so future information is likely to be more detailed 253 
in terms of specific diagnosis, and scope. This is particularly true in the areas of psycho-254 
social health and ophthalmology. Previous outbreaks have reported psychosocial problems 
2
 255 
although it is not included in all reports 
5
. Psycho-social problems are also evident in our 256 
patient group, although not captured in the documentation to date. Improved collaboration 257 
with the hospital’s mental health team should improve both the care and documentation in the 258 
future. Anecdotal evidence from the survivors’ clinic suggests that more subtle neurological 259 
problems such as specific nerve palsies may feature more heavily in a follow-up study.   260 
 261 
We would expect that the criteria and definition of PES will continue to develop and that the 262 
patients continue to present with fresh challenges. During the height of the epidemic, when 263 
these consultations took place, resources, and equipment for assessing survivors was very 264 
limited. This survey documents symptoms only in the first two weeks of discharge. 265 
Subsequent follow-up may be more detailed and benefit from increased resources, and 266 
symptoms continue to develop with time. Indeed the virus can cross the blood brain barrier 267 
during the acute illness 
12
 , and persist in some compartments for some months
13
 .  PES may 268 
continue to present new challenges.  Areas for development include: comparison of 269 
symptoms to community controls, psycho-social problems, the aetiology of ocular problems 270 
and musculoskeletal pain, and longitudinal description of the clinical picture.  271 
 272 
Musculoskeletal pain is a common complaint in the general population in Sierra Leone (J 273 
Whitworth pers comm), so a community controlled comparison will be important. In 274 
survivors of the Kikwit Ebola Zaire outbreak in 1995, Rowe et al. reported that their key 275 
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features: Arthralgia, myalgia, abdominal pain, fatigue and anorexia were more common in 276 
convalescents than household contacts, whereas fever, headache, diarrhoea, dyspnea, hiccups, 277 
haemorrhage were the same in survivors and the control group
5
. A topic for future research is 278 
the longitudinal course of recovery. Wendo et al 
2
 report that one year after the Ebola Zaire 279 
outbreak in Uganda, 25% of patients were still reporting to clinic. We can expect therefore 280 
some patients to have long term clinical needs. The epidemic is waning but the burden of 281 
disease it caused will remain for some time to come. 282 
 283 
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Note to editors: The image of the histogram has been uploaded separately as a 600dpi tif file. 338 
We would envisage this being presented in conjunction with this small table as a single 339 
figure. I have left this separate according to the instructions to authors to maximise 340 
editability. 341 
 342 
 343 
  344 
Figure 1.  Age distribution of patients presenting to the 34
th
 Military Hospital Ebola 
Survivor’s Clinic.  
 Male Female Total 
N 21 22 44 
Median 30 25 25 
IQR 22-37 20-34 20-37 
Range 10-52 8-70 8-70 
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Table 1: The frequencies of musculoskeletal symptoms. 
Some individuals complained of more than one area of pain. 
There was no statistically significant difference between the 
proportion of males and females suffering from 
musculoskeletal pain. (Chi
2
, p=0.7). 
 
 
  
 
Sex 
 Area of Pain Male Female Total 
    Joint  Unspecified 5 9 14 
Knee Unspecified 2 0 2 
Right Knee Joint 0 1 1 
Shoulder Joint 1 1 2 
    Generalised Body 4 4 8 
Upper Back Pain 1 3 4 
Musculo-skeletal  
Unspecified 2 0 2 
Left Thigh 1 1 2 
Lower Limb 0 1 1 
Right Thigh 1 0 1 
Gluteal Muscle 1 0 1 
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Table 2:  Ocular Symptoms: described by patients. Two patients were children and four were 346 
adults.  347 
 348 
Age Sex Symptom 
8 F eye pain 
14 F clear eye discharge 
20 F clear eye discharge 
28 F red eyes and 
blurred vision on 
the left 
29 F red eyes 
46 M blurred vision 
 349 
  350 
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Table 3: Number of patients presenting with of other presenting complaints 351 
Presenting 
Complaint 
N % Confidence 
Intervals 
(%) 
Cough 5 11 4-25 
Abdominal pain 4 9 3-22 
Chest pain 4 9 3-22 
Itching 4 9 3-22 
Insomnia 3 7 1-19 
Fever 3 7 1-19 
Loss of appetite 3 7 1-19 
Laboured speech 2 5 1-15 
Epigastric pain 2 5 1-15 
Rash 2 5 1-5 
17 other 
symptoms* 
1 2 0-12 
 352 
*Weight Loss, Hiccups, increased appetite, chest pain, sneezing, diarrhoea, vomiting, left 353 
sided weakness with facial nerve palsy, breathlessness, rash, dry flaky skin, earache, fever 354 
blister/cold sore, left scrotal swelling, nasal congestion, tremors 355 
 356 
 357 
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Figure 2. 359 
A scale Venn diagram illustrating the overlap between the three main symptom groups.  360 
Seven patients did not have any other the three main symptom groups. 361 
 362 
    363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
 372 
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